March 5, 2013 7:30 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Brinson Patrick initiated coverage on Zogenix (NASDAQ: ZGNX) with a Market Outperform rating and a $5.00 price target.Brinson Patrick commented, "Given the number of issues surrounding the FDA's decision on Zohydro ER's approval, we had suspected the FDA would take actions that would put Zohydro ER at a marketing disadvantage to the other extended release opioids. But as a result of Zogenix's informal communications with the agency last week, we believe Zohydro ER will be approved in the next few weeks with prescribing and distribution restrictions that are similar to other extended release opioids. Not only did the FDA not ask for additional data or issue a three month extension, but in Zogenix's press release the company described Zohydro ER's REMS as “consistent with...” similar drugs."Zogenix closed at $1.87 on Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.